Fulcrum Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview

Fulcrum Therapeutics

10/05/2024 17:13

* Fulcrum Therapeutics Inc  FULC.OQ   FULC.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 13
for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 22.1% increase in revenue to $360.14 thousand from $295
thousand a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fulcrum Therapeutics Inc
is
for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fulcrum
Therapeutics Inc is $14.50​, above​ its last closing price
of $7.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.42       -0.43      -0.40     Beat    6
 Sep. 30 2023  -0.43       -0.43      -0.39     Beat    10.3
 Jun. 30 2023  -0.45       -0.44      -0.38     Beat    14.5​
 Mar. 31 2023  -0.47       -0.46      -0.41     Beat    10
 ​​Jan.        -0.51       -0.49      -0.50     Missed  -2.1
 1 0001                                                 
 Sep. 30 2022  -0.62       -0.61      -0.51     Beat    16.7​
 Jan. 1 0001   -0.66       -0.66      -0.83     Missed  -25.6
 Jan. 1 0001   -0.62       -0.63      -0.64     Missed  -2.1
 This summary was machine generated May 10 at 16:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)